AACR roundup: Merus eyes accelerated approval; Immuneering accelerates RAS drug
Merus offered an interim look at an ongoing Phase I/II trial for its bispecific antibody petosemtamab on Monday, showing an overall response rate of 37.2% in previously treated head and neck cancer patients.
CEO Bill Lundberg said on an investor call on Monday that the company believes petosemtamab has the potential to become a new standard of care in head and neck squamous cell carcinoma.
The experimental drug is designed to bind to cancer cells expressing EGFR and LGR5. At the Feb. 1 cutoff, 49 patients had been treated with the recommended Phase II dose, though only 43 were evaluable for efficacy. Five patients couldn’t be evaluated because they withdrew after experiencing infusion-related reactions, Merus said on an investor call.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 170,200+ biopharma pros reading Endpoints daily — and it's free.